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APRI, AST-to-platelet ratio index.Methods: qFibrosis was established as a combined index based
on 87 parameters of architectural features. Images acquired from
25 Thioacetamide-treated rat samples and 162 CHB core biopsies
were used to train and test qFibrosis and to demonstrate its
reproducibility. qFibrosis scoring was analyzed employing Meta-
vir and Ishak ﬁbrosis staging as standard references, and collagen
proportionate area (CPA) measurement for comparison.
Results: qFibrosis faithfully and reliably recapitulates Metavir
ﬁbrosis scores, as it can identify differences between all stages
in both animal samples (p <0.001) and human biopsies
(p <0.05). It is robust to sampling size, allowing for discrimination
of different stages in samples of different sizes (area under the
curve (AUC): 0.93–0.99 for animal samples: 1–16 mm2; AUC:
0.84–0.97 for biopsies: 10–44 mm in length). qFibrosis can signif-
icantly predict staging underestimation in suboptimal biopsies
(<15 mm) and under- and over-scoring by different pathologists
(p <0.001). qFibrosis can also differentiate between Ishak stages
5 and 6 (AUC: 0.73, p = 0.008), suggesting the possibility of mon-
itoring intra-stage cirrhosis changes. Best of all, qFibrosis demon-
strates superior performance to CPA on all counts.
Conclusions: qFibrosis can improve ﬁbrosis scoring accuracy and
throughput, thus allowing for reproducible and reliable analysis of
efﬁcacies of anti-ﬁbrotic therapies in clinical research and practice.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.14 vol. 61 j 260–269
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Introduction
Excessive accumulation of extracellular matrix (ECM) results in
ﬁbrosis, which is the hallmark of chronic liver diseases (CLD)
[1]. Progression of liver ﬁbrosis is closely related to the devel-
opment of major complications of CLD [2]. Chronic hepatitis B
(CHB), a leading global health burden, is the major cause of cir-
rhosis and liver cancer [3]. With recent advances in efﬁcacious
antiviral therapies, the endpoint of ﬁbrosis/cirrhosis regression
can be achieved in long-term treatment of CHB [4]. Herein lies
an increasing need for accurate and precise assessment of
ﬁbrosis, a prognostic indicator of chronicity and CLD sequelae,
in order to facilitate and monitor the effective utilization of
therapeutic advances [5].
Liver biopsy has long been the gold standard for ﬁbrosis
assessment in CLD [6]. It has the capability of providing his-
topathological information on various morphological parame-
ters that have been clinically validated for their
pathophysiological relevance, but are not obtainable with
non-invasive techniques [7,8] such as liver stiffness measure-
ments [9] and biochemical markers [10]. Currently, liver
biopsy-based assessment remains the standard reference for
monitoring therapeutic responses in both clinical research tri-
als and actual practice [4,11].
However, conventional histological staging of ﬁbrosis in
liver biopsy is semiquantitative and highly subjective to sam-
pling error and observer variations, as it basically relies on a
global assessment of architectural distortion and associated
ﬁbrosis. It cannot sufﬁciently and reliably reﬂect the compli-
cated pathophysiological/functional status of the liver, which
is incumbent for diagnostic decision-making in current CLD
management [5,12]. Furthermore, cirrhosis has recently been
redeﬁned to be a dynamic process with intra-stage progres-
sive/regressive changes [13]; in this regard, the International
Liver Pathology Study Group has called for biopsy-based histo-
logical markers that can quantify and predict intra-stage cir-
rhosis changes [14]. Thus, technologies that can provide
feasible solutions to these issues may potentially improve
ﬁbrosis assessment in CLDs such as CHB.
Image-based morphometric analysis of biopsy samples has
been explored as an alternative to histological staging systems
[15]. The current method of choice is collagen proportionate
area (CPA) measurement, which quantiﬁes the extent of collag-
enous ECM deposition without incorporating architectural
information about the damaged tissue landscape [15–17]. CPA
correlates well with late stages of ﬁbrosis but is highly sensi-
tive to sample size [18]. Clinical applicability of CPA is still
being critically evaluated.
The strengths and limitations of current assessment systems
motivated us to develop an innovative method – qFibrosis for
liver biopsy assessment, based on the strategy of combining
pathology-relevant collagen architectural features with auto-
mated computer-aided image analysis tools. With input of imag-
ing data from the liver sample, qFibrosis can automatically
compute the fully quantitative ﬁbrosis scores based on the
respective collagen architectural features. Such a strategy poten-
tially overcomes some limitations of the biopsy-based histologi-
cal ﬁbrosis assessment with a more accurate and quantitative
staging methodology. Here we report the development of qFibro-
sis and verify its potential as a ﬁbrosis assessment tool in both
animal model and CHB patients.Journal of Hepatology 201Materials and methods
Thioacetamide-induced liver ﬁbrosis in rats
The Thioacetamide (TAA)-induced animal model is used for studying liver ﬁbrosis
in rats. All the protocols for studying TAA-induced liver ﬁbrosis rat models were
reviewed and approved by the Biological Resource Centre (BRC) Institutional Ani-
mal Care and Use Committee (IACUC). Twenty-ﬁve rats were randomly separated
into 5 groups, representing 5 time points – without drug treatment, and treated
with TAA for 4, 8, 10, and 12 weeks. Liver specimens from the left lateral lobe of
each animal were formalin-ﬁxed, parafﬁn-embedded, and sectioned into consec-
utive slices of 50 lm for direct SHG-imaging and Masson Trichrome staining for
histological examination [19]. Scoring was performed by an experienced pathol-
ogist using the Metavir ﬁbrosis staging system [18].
Human biopsy samples
Clinical biopsy samples from two independent cohorts were included: 107 non-
fragmented liver core biopsies for algorithm training and testing, and another
well-balanced 55 long core biopsy samples for demonstrating the technology
reproducibility and robustness. Both cohort samples were from CHB patients in
Nanfang Hospital (Guangzhou, China). The clinical study was conducted accord-
ing to the Declaration of Helsinki guidelines and approved by the Ethical Commit-
tee of Nanfang Hospital. All patients have given written informed consent for liver
biopsy as well as permission for use of their medical records. The average length
of the 107 biopsies was 16.7 ± 5.4 mm (minimum length: 10 mm, maximum
length: 30 mm). The average length of the 55 biopsies was 30.4 ± 4.4 mm (mini-
mum length: 25 mm, maximum length: 44 mm).
All the liver biopsy specimens were routinely processed by formalin ﬁxation
and parafﬁn-embedding, sectioned at 5 lm thickness for SHG-imaging, and then
stained with Masson Trichrome for histological assessment. Biopsy samples were
read independently by one hepatopathologist (A.W.) and one junior pathologist
(W.S.), and staged using Metavir and Ishak ﬁbrosis scoring systems. The detailed
distribution of all biopsies, together with their Metavir ﬁbrosis stages is summa-
rized in Supplementary Table 1.
Image acquisition
The 107 samples for training and testing qFibrosis were imaged by the system of
second harmonic generation/two photon excitation ﬂuorescence (SHG/TPEF)
microscopy established and adjusted as previously reported [19] at the Institute
of Bioengineering and Nanotechnology, Singapore. Image acquisition was per-
formed with a 20 objective on unstained sections of the tissue samples. To cover
most of the sample areas, 3 nine-by-nine multi-tile images were acquired for the
animal samples with a ﬁnal image size of 16 mm2 (4  4 mm); and up to 10
three-by-three multi-tile images for each human biopsy sample with ﬁnal image
size of 1.8 mm2 (1.35  1.35 mm). The additional 55 samples to demonstrate
reproducibility and robustness (or the degree of insensitivity to different image
acquisition methods) were imaged by Genesis system (HistoIndex, Singapore),
an SHG/TPEF technology-based commercial device, at Southern Medical Univer-
sity (Guangzhou, China). Image acquisition parameters for these samples were
set the same as the ones for the former cohort samples.
Establishing and measuring qFibrosis
The procedure for establishing qFibrosis includes (i) identiﬁcation of different col-
lagen patterns, (ii) extraction of collagen architectural features, and (iii) statistical
analysis of features of the respective collagen patterns, which were then com-
bined into a single index. Detailed descriptions of the protocols are provided in
Supplementary Materials and methods.
The acquired images of samples were processed and calculated with the
established qFibrosis. A numerical value between 0 and 1 was assigned to each
sample while the higher value indicates more severe ﬁbrosis.
Statistical analysis
The two-tailed Wilcoxon rank-sum test was performed to estimate the statistical
differences of CPA and qFibrosis index between different Metavir and Ishak ﬁbro-
sis stages, and differences of clinical measurements between Ishak stages 5 and 6.
The DeLong test was used to compare the receiver-operating-characteristics
curves (ROCs) and area under ROCs (AUCs) of qFibrosis and CPA. The stepwise
logistic regression was performed to ﬁnd the best combination of markers to dif-
ferentiate Ishak stages 5 and 6. Statistical signiﬁcance level was set as p <0.05.4 vol. 61 j 260–269 261
Research Article
Results
qFibrosis, an automated assessment of changes in collagen patterns
and quantiﬁcation of liver ﬁbrosis
We employed the Metavir ﬁbrosis staging system to illustrate the
histopathological architectural features of the various collagen
patterns acquired in CHB [20] (Fig. 1A). The main collagen pat-
terns, namely, portal collagen (portal expansion), septal collagen
(bridging ﬁbrosis), and ﬁbrillar collagen (ﬁne collagen distributed
in the pericellular/perisinusoidal space of Disse) were identiﬁed
through image acquisition and processing, and translated into
quantitative parameters to build up qFibrosis indices (Fig. 1B
and C). In the statistical analysis framework of qFibrosis
(Fig. 1C), a list of 87 collagen architectural features (Supplemen-
tary Tables 2–4) was categorized into 3 groups, namely, portal,
septal, and ﬁbrillar collagen; feature selection was performed to
identify the most important architectural features [21]; principal
component analysis was used to reduce the dimension of the
selected features [22]; and multinomial logistic regression was
performed to combine the principal components of the 3 sub-
groups (subindices) into a single index, qFibrosis. The potential
use of qFibrosis in routine clinical practice is illustrated in Fig. 2.qFibrosis scoring can faithfully replicate Metavir ﬁbrosis staging
We ﬁrst investigated the performance of qFibrosis to replicate the
ﬁbrosis scores obtained with conventional histological assess-
ment such as Metavir staging system. qFibrosis reﬂected a contin-
uum of ﬁbrosis progression that was consistent with Metavir
ﬁbrosis stages in both animal model and CHB patients, of which
the values are summarized in Tables 1 and 2, respectively.
In the rat model, 75 liver tissue images (16 mm2) were quan-
tiﬁed with 15 images from each stage. qFibrosis values increased
with ﬁbrosis progression and showed signiﬁcant differences
between all the stages (p <0.001) (Fig. 3A). CPA showed drastic
changes only in late stages and could not differentiate between
early stages (stages 1 and 2) (Fig. 3B). In the CHB biopsies, qFibro-
sis values, obtained from 69 biopsies longer than 15 mm, success-
fully differentiated between all stages (p <0.05) (Fig. 3C). In
comparison, CPA could only differentiate between stages 3 and
4 (stages 1 vs. 2, p = 0.124; stages 2 vs. 3, p = 0.194) (Fig. 3D).qFibrosis is less sensitive to sampling error
Sampling error is a major limitation when applying quantiﬁca-
tion methods such as CPA [18]. To assess the sensitivity of qFibro-
sis to sampling error, we ﬁrst performed a proof-of-concept
demonstration with animal samples. Different sizes were divided
from a large-size section of liver containing a sufﬁcient number of
portal tracts for accurate scoring by an experienced pathologist.
Images of the large sections were cropped to simulate samples
of varying sizes (Supplementary Fig. 1). The coefﬁcient of varia-
tion (CV) of qFibrosis was calculated for each sample at different
sizes; the CV values gradually increased from 18% to 28% whilst
the sample sizes decreased from 8 mm2 to 1 mm2 (Fig. 4A). In
contrast, the CV of CPA increased more drastically from 20% to
46% for the same sample size (Fig. 4A). The CV of qFibrosis was
signiﬁcantly smaller than that of CPA for samples sizes at
4 mm2 (p = 0.02), 2 mm2 (p <0.001), and 1 mm2 (p <0.001).262 Journal of Hepatology 201The performances of qFibrosis vs. CPA for ﬁbrosis scoring with
different sample sizes were evaluated with ROC analysis (Supple-
mentary Fig. 2, Supplementary Table 5). The AUC values of
qFibrosis decreased slightly along with the reduction in sample
sizes (Fig. 4B). CPA achieved similar AUC values as qFibrosis using
large samples at 16 mm2; however, the AUC values of CPA
decreased drastically when the sample sizes were reduced
(Fig. 4B). The differences of AUC between qFibrosis and CPA val-
ues became signiﬁcant at half (8 mm2) (stages 0 vs. 1, 2, 3, 4 and
0, 1 vs. 2, 3, 4; p <0.05, respectively) to one fourth (4 mm2) (all
stages, p <0.001) of the original size for differentiating liver ﬁbro-
sis stages. The performance achieved by qFibrosis at 1 mm2 sam-
ple size (AUC: 0.95–0.93) was similar to that obtained by CPA at
sample size of 8 mm2 (AUC: 0.96–0.90).
In the clinical scenario provided by the CHB biopsies, the AUC
values of qFibrosis for the detection of different stages of ﬁbrosis
on 69 samples longer than 15 mm were from 0.92 to 0.84, while
the AUC values of CPA were smaller (0.76–0.71) (Fig. 4C, Supple-
mentary Table 6). We further evaluated qFibrosis on all 107 non-
fragmented human core biopsy samples that included both long
(P15 mm) and short samples (<15 mm), as short samples are
unavoidable in routine clinical practice. AUC values of qFibrosis
were maintained at higher than 0.8 for detection of signiﬁcant
ﬁbrosis and cirrhosis, whereas the AUC of CPA dropped to 0.71
(Fig. 4D, Supplementary Table 6). Thus, we demonstrated that
qFibrosis can potentially differentiate ﬁbrosis at different stages
in core biopsy samples of different sizes.
qFibrosis can aid in correction of sampling error-mediated intra-
observer variation
Short core biopsy samples are known to yield underestimated
scores in ﬁbrosis staging [23]. We simulated the scenario of a
pathologist scoring short core biopsy samples to investigate
whether qFibrosis can identify the potential underestimation.
We used all 69 good quality (P15 mm) biopsy samples to train
a multinomial logistic regression model and applied it to the
remaining 38 suboptimal (<15 mm) biopsy samples to obtain
qFibrosis values. The underestimation of ﬁbrosis stages by
pathologists on suboptimal biopsy samples was accurately pre-
dicted by qFibrosis (Fig. 4E). CPA cannot predict the underestima-
tion in all stages except for stage 4 (Fig. 4E). It is generally
accepted that there is rare underestimation of Metavir F4 sam-
ples. Therefore, qFibrosis can potentially aid pathologists to
adjust for the degree of aggressive vs. conservative scoring deci-
sions to compensate for sampling error-mediated intra-observer
variation.
qFibrosis can aid in correction of inter-observer variation
We investigated whether qFibrosis can identify the trend of devi-
ation of a pathologist’s scoring with reference to an experienced
pathologist’s scores. All 107 human samples were independently
scored by two pathologists, A and B. Cohen’s and Fleiss’s kappa
statistics were used to assess the inter-observer agreement
between two (Cohen’s) or any number (Fleiss’s) of observers.
The Cohen’s kappa of the scores from the two pathologists was
0.40 (p <0.001), suggesting a fair but not strong agreement (Sup-
plementary Fig. 3). Forty-nine out of 107 human samples with
available FibroScan measurements were chosen to compare
the consistency of ﬁbrosis scores by the two pathologists. The4 vol. 61 j 260–269
Fig. 1. Schematic illustration of qFibrosis establishment. (A) Representation of changes in collagen patterns in chronic liver disease based onMetavir staging system. Portal,
septal and ﬁbrillar collagen are denoted in blue, green and red, respectively. (B) The 3 types of collagen patterns are shown in Thioacetamide (TAA)-induced rat liver samples
with normal and advanced ﬁbrosis, as visualised by Masson Trichrome-stained, TPEF/SHG and processed images. (C) Computation framework to establish qFibrosis.
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Fig. 2. Illustration of qFibrosis application in liver biopsy-based ﬁbrosis assessment. Conventional histological assessment of liver ﬁbrosis requires human observation
of microscopic images from stained tissue sections. qFibrosis provides fully-automated, computer-aided liver ﬁbrosis staging, which is fast, quantitative and consistent.
Table 1. qFibrosis values of Thioacetamide-treated animal samples.
Fibrosis-qFibrosis
Fibrosis-metavir score Percentage of total 25th percentile 75th percentile Median Mean SEM
F0 (n = 15) 20.0 0.016 0.144 0.049 0.074 0.017
F1 (n = 15) 20.0 0.157 0.410 0.258 0.266 0.040
F2 (n = 15) 20.0 0.350 0.504 0.429 0.434 0.031
F3 (n = 15) 20.0 0.743 0.854 0.751 0.779 0.025
F4 (n = 15) 20.0 0.968 1.000 0.998 0.956 0.021
SEM, standard error of mean.
Table 2. qFibrosis values in 69 chronic hepatitis B core liver biopsies longer than 15 mm.
Fibrosis-qFibrosis
Fibrosis-metavir score Percentage of total 25th percentile 75th percentile Median Mean SEM
F1 (n = 12) 17.4 0.257 0.493 0.374 0.411 0.051
F2 (n = 9) 13.0 0.445 0.783 0.590 0.607 0.073
F3 (n = 18) 26.1 0.640 0.919 0.809 0.761 0.047
F4 (n = 30) 43.5 0.776 0.995 0.933 0.892 0.023
SEM, standard error of mean.
Research Articlecut-off values of non-invasive ﬁbrosis markers, such as Fibro-
Scan, APRI, and FIB-4, to predict cirrhosis (F4) or signiﬁcant
ﬁbrosis (F2-4) were established in large cohort studies of CHB
patients [24–26]. The scores from pathologist A were more con-
sistent with all the clinical markers (with higher Fleiss’s kappa
indicating stronger overall agreement) than pathologist B (Sup-
plementary Table 7). Thus, scores from pathologist A were used
to train the multinomial logistic regression model to yield qFibro-
sis values for all 107 samples. Compared to the scores from
pathologist A, the scores from pathologist B were overestimated
and underestimated by 3.7% and 42%, respectively. Such over-
and underestimation can be accurately predicted by qFibrosis
but not by CPA (Fig. 4F). Thus, qFibrosis can aid in the correction
of inter-observer variation in ﬁbrosis assessment by serving as a
reliable proxy for experienced pathologists.264 Journal of Hepatology 201qFibrosis can aid in detection and monitoring of intra-stage cirrhosis
changes
To differentiate intra-stage cirrhosis changes, we calculated
qFibrosis values from 43 human samples that were categorized
as cirrhosis (F4) on Metavir and under two substages 5 and 6
according to Ishak staging. qFibrosis accurately differentiated
these two substages (p = 0.008) with AUC of 0.73 whereas CPA
failed to do so (p = 0.302) (Fig. 4G, Supplementary Fig. 4A). We
also investigated whether the combination of qFibrosis with
non-invasive clinical markers would improve the detection of
intra-stage cirrhosis. Nine routine clinical biomarkers and stiff-
ness measurement by FibroScan were ﬁrst assessed in 17 of
the 43 Metavir F4 samples, which had complete clinical data;
only FibroScan could differentiate intra-stage cirrhosis changes4 vol. 61 j 260–269
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Fig. 3. qFibrosis faithfully matches Metavir ﬁbrosis staging. (A) Changes of
qFibrosis with ﬁbrosis progression between the various stages in Thioacetamide
(TAA)-treated animals (p <0.001). (B) Changes of collagen proportionate area
(CPA) with ﬁbrosis progression in TAA-treated animals. (C) Changes of qFibrosis
with ﬁbrosis progression between the various stages in core biopsy samples from
chronic hepatitis B patients (p <0.05). (D) Changes of CPA with ﬁbrosis progres-
sion in the same core biopsies. The boxes indicate the median, 25th and 75th
percentiles, whereas vertical bars display the adjacent value and ‘ + ’ symbols
represent outliers.
JOURNAL OF HEPATOLOGYamongst these markers (Table 3). By stepwise logistic regression
analysis, including all 10 markers together with qFibrosis and
CPA, the combination of qFibrosis, FibroScan, and international
normalized ratio (INR) was the most predictive for differentiating
intra-stage cirrhosis (Supplementary Table 8); the AUC improved
from 0.81 (qFibrosis only) to 0.93 (combination of qFibrosis,
FibroScan, and INR) (Supplementary Fig. 4B). Thus, qFibrosis
can differentiate intra-stage cirrhosis changes alone or in combi-
nation with FibroScan and INR.
Validation of qFibrosis on an independent cohort of CHB biopsy
samples
We further tested the reliability of qFibrosis on images acquired
by a commercial SHG/TPEF imaging device on another 55 core
biopsy samples. The values of qFibrosis faithfully replicated
Metavir ﬁbrosis scoring as indicated in the previous experiments,
with better differentiation ability between stages than with CPA
measurements (Supplementary Fig. 5A and B). The performances
of both qFibrosis and CPA were improved in this cohort due to the
good sample quality (average length of 30.4 ± 4.4 mm), but
qFibrosis still performs better than CPA. The AUC values of
qFibrosis for detection of different stages were from 0.90 to
0.95, while the AUC values of CPA were smaller (0.84–0.92) (Sup-
plementary Fig. 5C–E).Discussion
By incorporating spatial architectural features of pathological rel-
evance at tissue level, we have established a fully-quantitative
method – qFibrosis – that can reliably stage liver ﬁbrosis with
reduced variability of sampling error and inter-/intra-observer
bias in assessment of both animal samples and CHB core biopsies.Journal of Hepatology 201In addition, qFibrosis can differentiate late stages in ﬁbrosis based
on the Ishak scoring system, which suggests a potential to aid the
monitoring of intra-stage cirrhosis changes.
qFibrosis establishment is based on two key elements. One is
the suitable imaging technique for efﬁcient collection of tissue
architectural information. For this purpose, we employed the
non-linear optical SHG/TPEF microscopy that was previously
reported [19] and a commercial SHG/TPEF imaging device for
comparison. SHG/TPEF can quantify and localise collagen in 2D
and 3D formats by collagen’s intrinsic optical properties in the
stain-free samples [27], so as to accurately identify and discrim-
inate the spatial parameters of the respective collagen patterns.
Another is the quantitative identiﬁcation of histopathological
architectural features. We used the TAA-treated animal model
to simulate the changes of CHB liver ﬁbrosis [28], for serial sam-
pling to sufﬁciently accumulate, select, and test the parameters of
image analysis; so that diversity and quality of tissue samples
were guaranteed for appropriate pre-acquisition of architectural
information for setting-up the qFibrosis framework. All the con-
siderations were justiﬁed by the improved results of qFibrosis
performance testing in animal samples.
Histological staging is the fundamental concept for qFibrosis
design. In order to fully recapitulate the informative characteris-
tics of traditional descriptive assessment, we designed the
qFibrosis index to encompass three key morphological pheno-
types of common pathological interest, and quantiﬁed them into
three subindices by measuring the spatial parameters of ﬁbrillar
collagen within the individual phenotypic location. We observed
that during the dynamics of ﬁbrosis development, there were dif-
ferent trends of change between the three subindices (Supple-
mentary Figs. 8–11); suggesting that qFibrosis might be used to
sensitively and precisely monitor the independent evolution of
different collagen patterns. This potential can be further explored
to address the emerging needs for insightful analysis into the
pathophysiological developments occurring in different types of
CLDs [5]. We set the Metavir system as the reference to develop
qFibrosis; other systems such as Knodell and Ishak systems can
also be conveniently translated into qFibrosis, since they essen-
tially employ the similar architectural principles to categorize
liver disease stages [11]. Within the framework of histopatholo-
gical categorization, qFibrosis provides scores of continuous vari-
ables derived from its inherent full-quantiﬁcation algorithm;
thus, it could potentially have discriminative power for precisely
reﬂecting the dynamics of ﬁbrosis/cirrhosis progression or
regression.
Employing the similar imaging technique, Gailhouste et al.
ﬁrst comprehensively validated SHG on 119 clinical liver tissue
samples of mixed CLDs for scoring the amount of ﬁbrosis via
detecting ﬁbrillar collagen density, which is similar to CPA
measurement [16]. Our present study is innovative in its strat-
egy for establishing the qFibrosis index with histopathological
architectural features by quantitatively deﬁning the spatial
parameters of ﬁbrillar collagen. Another distinct contribution
of our study is that qFibrosis was specially trained and vali-
dated with CHB samples; thus, promoting the ready applicabil-
ity of our method to align closely with clinical practice of this
particular disease.
We further analysed the performance of qFibrosis against CPA.
While CPA showed limitations in discrimination accuracy and
higher sensitivity to sampling error, as reported previously
[11,18], qFibrosis exhibited signiﬁcantly improved capacity to4 vol. 61 j 260–269 265
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Fig. 4. qFibrosis is superior to collagen proportionate area (CPA) in resolving biopsy-related issues of sampling error, inter-/intraobserver variation, and intra-stage
discrimination in cirrhosis. (A) Coefﬁcient of variance of qFibrosis and CPA in animal samples (⁄p <0.05). (B) Area under ROC curve (AUC) values of qFibrosis and CPA at all
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Research Articleovercome the above limitations (Figs. 3 and 4). Considering the
strategy taken for the qFibrosis design, it is rational that qFibrosis
would behave more similarly to a conventional histological266 Journal of Hepatology 201assessment system than CPA. This partly accounts for the robust-
ness of qFibrosis to sample size-dependent sampling error (i.e.,
sample adequacy). On the other hand, CPA has signiﬁcant4 vol. 61 j 260–269
Table 3. Comparison of qFibrosis, collagen proportionate area (CPA) and
clinical parameters for Ishak stages 5 and 6.
Ishak stage 5 Ishak stage 6 p value
CPA (%) 4.61 ± 2.30 7.22 ± 3.58 0.08
qFibrosis (a.u.) 0.80 ± 0.16 0.94 ± 0.08 0.03
ALT (IU/L) 149.33 ± 70.70 214.9 ± 236.9 0.44
AST (IU/L) 110.33 ± 64.25 136.56 ± 82.84 0.46
ALB (g/L) 43.89 ± 4.61 43.01 ± 1.57 0.6
TBIL (mol/L) 23.51 ± 21.18 20.90 ± 5.64 0.73
INR (a.u.) 1.11 ± 0.09 1.11 ± 0.08 0.9
PT (s) 13.32 ± 1.14 13.28 ± 1.09 0.93
PLT (109/L) 199.67 ± 41.76 195.67 ± 30.63 0.82
FibroScan® (kPa) 9.93 ± 3.37 17.13 ± 8.79 0.04
APRI (a.u.) 1.10 ± 0.85 1.22 ± 0.58 0.74
FIB-4 (a.u.) 2.09 ± 1.59 2.80 ± 2.08 0.43
Data are Mean ± SD.
ALT, alanine transaminase; AST, aspartate transaminase; ALB, albumin; TBIL, total
bilirubin; INR, international normalized ratio; PT, prothrombin time; PLT, plate-
lets; APRI, AST-to-platelet ratio index; and FIB-4, FIB-4 index.
JOURNAL OF HEPATOLOGYdeviation between different samples of the same stage scores,
since histological staging and amounting ﬁbrosis (CPA) are
entirely different assessments [11,29]. Collectively, the results
not only support the technical strength of qFibrosis for future
applications, but also support our hypothesis that the improved
discriminative power of qFibrosis is due to the additional input
of histopathological architectural features.
We also showed that the performance of qFibrosis is repro-
ducible between the original cohort of 107 samples and the inde-
pendent cohort of 55 samples imaged by different SHG imaging
devices. qFibrosis is highly reproducible when the image quality
is reasonably consistent. The variations of SHG images due to dif-
ferent sample processing procedures or different imaging sys-
tems can be corrected using different optical settings and be
calibrated according to Guilbert et al. [30]. Since qFibrosis
depends on the spatial collagen information relative to tissue
architectural features rather than on the absolute quantity of col-
lagen intensity signal, this method is necessarily less sensitive to
imaging or staining quality variation than other intensity-depen-
dent methods such as CPA. Thus, qFibrosis is a robust quantitative
staging method that would be suitable for the potential multicen-
ter clinical research studies where sample processing and image
acquisition variation would be unavoidable.
There are several exciting areas in which qFibrosis may have a
role in the near future. First is in the realm of antiviral clinical
research and management of CHB. It has been veriﬁed recently
that long-term effective antiviral therapy can lead to regression
of liver ﬁbrosis and cirrhosis in CHB patients [4]. Histological
analysis is currently the standard reference for performing the
evaluation. Primarily established and validated with CHB sam-
ples, qFibrosis may soon be sufﬁciently improved to serve as an
automatic and reliable adjunctive tool for liver biopsy evaluation.
Second would be potentially in the area of cirrhosis assessment.
Regression of cirrhosis has now been observed with the availabil-
ity of HBV potent therapy [31], bringing with it increasing
requirement for the assessment of regression and substaging
[5,14]. qFibrosis could differentiate between Ishak stages 5 and
6; with the potential to detect the changes of histological pat-
terns in cirrhosis progression or regression through the quantita-
tive classiﬁcation of different collagen patterns. In future studiesJournal of Hepatology 201correlating with or complementing other clinical markers such as
FibroScan [32] and hepatic vein pressure gradient (HVPG) [33]
or complications of cirrhosis, we could further develop qFibrosis
into a tool to aid monitoring the cirrhosis dynamics. Last but not
least, since experienced hepatopathologists are a rare breed in
most setups, qFibrosis might act as a valuable aid to pathologists
to produce consistent staging of liver ﬁbrosis; as well as to pro-
vide on-site expert consultation to the non-expert pathologists.
In laboratories without SHG microscopy, qFibrosis values can be
obtained from images of stained biopsy samples using routine
light microscopy, as long as accurate identiﬁcation of collagen
can be ensured. The examples of both Masson Trichrome-stained
and Sirius Red-stained images with qFibrosis evaluation are
shown in Supplementary Fig. 6.
Performance of qFibrosis can be affected by the quality of
samples in the training set; as evident from the higher AUC val-
ues obtained in staging larger animal samples in our results. This
is because establishment of qFibrosis is basically the generation
of an algorithm by training-and-learning with the sample’s imag-
ing data. Thus, in future work, more qualiﬁed biopsy samples for
training purpose can further improve the performance of qFibro-
sis; and recruiting a larger set of samples for a multicentre clini-
cal study would be necessary to generalize the capability of
qFibrosis and validate its clinical applications. Fragmented biop-
sies are unavoidable in clinical practice due to the selection of
sampling techniques [34]. In this study, we only selected non-
fragmented biopsies for training and testing qFibrosis for accu-
racy in histological scoring reference [12,23]. Our observation
that qFibrosis is less sensitive to sampling error suggests that
fragmented biopsies contain information potentially extractable
by qFibrosis. Further studies with large cohorts would be needed
to evaluate the degree of tolerable fragmentation, to repair and
partially reconnect the fragments by extrapolation, and to com-
plement the non-fragmented biopsies in applications.
Since its target sample is liver biopsy, however superior the
diagnosticutilityofqFibrosis, invasivenessof theassessment is still
an inherent limitation against its widespread application in pre-
ventive medicine. However, since liver biopsy provides compre-
hensive information not only on ﬁbrosis but also on
necroinﬂammation, steatosis, and other speciﬁc histopathological
features, the role of qFibrosis can be expandedwith the aid of TPEF
or other staining or non-staining imaging modalities to quantify
these other features. It is noteworthy to emphasize that caution
needs to be exercisedwhen applying qFibrosis to sampleswith sig-
niﬁcant amounts of these other histopathological features.
In summary, qFibrosis has been established and validated to
provide quantitative scores incorporating histopathological fea-
tures for liver ﬁbrosis evaluation. It faithfully recovers the staging
results of Metavir histological assessment system; while in the
meantime, effectively ameliorating the inherent issues of the cur-
rent systems regarding sampling error and observer variation. It
can also differentiate stages 5 and 6 in the Ishak system suggest-
ing the possibility of monitoring intra-stage cirrhosis changes.
qFibrosis can potentially be a valuable tool to enhance the utility
of liver biopsy for accurate and objective assessment of ﬁbrosis in
clinical research and management of CLD.Conﬂict of interest
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